Summary and Current Challenges of New Approach Methods for Industry

Paul Hanlon, PhD, DABT
Director of Regulatory Affairs
Abbott Nutrition

Columbus, Ohio
paul.hanlon@abbott.com
Conflict of Interest Statement

I am a full-time employee of Abbott Nutrition

The views and opinions expressed in this presentation are those of myself and do not necessarily reflect the position of Abbott Nutrition
Summary of Previous Presentations

- Analytical Challenges Related to the Analysis of Processing Contaminants in Foods and Impacts on Risk Assessment
  - Jessica Beekman, FDA
- Next Generation Systemic Toolbox
  - Matt Dent, Unilever
- Codex Alimentarius: Guidelines for Rapid Risk Analysis Following Instances of Detection of Contaminants in Food Where There is No Regulatory Level
  - Lauren Posnick Robin, FDA
- The Challenge of Assessing Minor Constituents: An Example from the Flavor Industry
  - Sean Taylor, Verto Solutions
Scope of the Issue

We live in a world of made of chemicals

- New analytical methods (NAMs) with lower detection capabilities will continue to increase the number of chemicals that can be detected in food

- Information about these chemicals ranges from:
  - Only detection with a suggestion of structure, to
  - Structural data, to
  - Data for related substances, to
  - Safety studies in non-oral route, to
  - Safety studies with relevance to food exposure
Ensuring the safety of the food supply is the goal of all stakeholders.

An increasing list of chemicals can be detected in food.

- How can we use NAMs to improve food safety **today**?
- What can we do to use NAMs more effectively **in the future**?
The Present and Future of NAMs for Food Risk Assessment

What is possible today?
- Prioritization of chemicals
- Identification of potential mechanisms of action

What is possible in the future?
- Replacing animal models for more toxicological endpoints
- Using NAMs to drive risk management decisions
Barriers to Broader Adoption of NAMs

**Science**
- Lack of harmonization on methods
- Lack of methods to address specific endpoints
- If even one regulator requires traditional animal data, it incentivizes conducting those studies

**Communication**
- Scientists are not aligned to the appropriateness of NAMs
- Consumers are risk adverse and may trust NAMs data showing a concern more than they trust NAMs data showing a chemical is safe
Where Do We Go From Here?
Roundtable Discussion

Moderator: Paul Hanlon

Paul Hanlon, Co-Chair

Stephen Hermansky, Co-Chair

Jessica Beekman
Matthew Dent
Suzanne Fitzpatrick
Lauren Robin
Sean Taylor